Prescribing information

 

       

Just under 50% of asthma patients on high-dose LABA/ICS remain uncontrolled1

 

46%

46%

of patients with asthma remain uncontrolled, despite current treatment with high-dose LABA/ICS*1

Persistence of symptoms puts patients at a higher risk of asthma attacks2

 

*Baseline data from a retrospective study of 45,804 adult asthma patients in the UK, newly initiated on medium- or high-dose LABA/ICS therapy.1

Indication: ENERZAIR® BREEZHALER® (indacaterol acetate/glycopyrronium bromide/mometasone furoate inhalation powder) is indicated as a maintenance treatment for asthma in adult patients not adequately controlled with a maintenance combination of a long-acting beta2-agonist and a high dose of an inhaled corticosteroid, who experienced one or more asthma exacerbations in the previous year.3

ICS, inhaled corticosteroid; LABA, long-acting beta2-agonist.

References

  1. Buhl R et al. Respir Med 2020;162:105859 [Epub ahead of print].
  2. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2020. Available at: https://ginasthma.org/wp-content/uploads/2020/04/GINA-2020-full-report_-.... Date accessed: December 2020.
  3. ENERZAIR BREEZHALER Summary of Product Characteristics.
Rate this content: 
No votes yet
UK | March 2021 | 103400
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]